Xenetic Biosciences (XBIO) Expected to Announce Earnings on Thursday

Xenetic Biosciences (NASDAQ:XBIO) is projected to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Xenetic Biosciences to post earnings of ($0.72) per share and revenue of $0.52 million for the quarter.

Xenetic Biosciences (NASDAQ:XBIO) last announced its earnings results on Tuesday, March 18th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.48). The business had revenue of $0.65 million for the quarter, compared to analysts’ expectations of $0.18 million. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. On average, analysts expect Xenetic Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Xenetic Biosciences Stock Performance

Shares of NASDAQ XBIO opened at $2.80 on Tuesday. Xenetic Biosciences has a fifty-two week low of $2.20 and a fifty-two week high of $5.20. The company has a market cap of $4.32 million, a PE ratio of -1.05 and a beta of 2.31. The business has a 50-day simple moving average of $3.00 and a two-hundred day simple moving average of $3.70.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a research note on Wednesday, April 9th.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.